BioPharmX Corp | Business Contracts

Form of Securities Purchase Agreement, dated October 3, 2022, by and among Timber Pharmaceuticals, Inc. and the purchaser signatories thereto (Filed With SEC on October 3, 2022)

Letter Agreement, dated July 27, 2022, between Timber Pharmaceuticals, Inc. and TardiMed Sciences LLC (Filed With SEC on August 2, 2022)

Form of Incentive Stock Option Grant Agreement (Filed With SEC on March 23, 2021)

Lease Agreement, effective as of March 10, 2021, by and between Timber Pharmaceuticals, Inc. and SIG 110 LLC (Filed With SEC on March 16, 2021)

Form of Indemnification Agreement (Filed With SEC on May 22, 2020)

Amendment No. 2 to Agreement and Plan of Merger, dated April 27, 2020, among BioPharmX, Timber and Merger Sub (Filed With SEC on April 27, 2020)

License Agreement, dated July 5, 2019, by and between AFT and Timber (Filed With SEC on February 20, 2020)

Form of Series 2 Warrant (Filed With SEC on October 3, 2022)

Form of Series 1 Warrant (Filed With SEC on October 3, 2022)

Form of Common Warrant (Filed With SEC on August 8, 2022)

Form of Pre-Funded Warrant (Filed With SEC on August 8, 2022)

Form of Securities Purchase Agreement (Filed With SEC on August 2, 2022)

Form of Common Warrant (Filed With SEC on August 2, 2022)

Form of Pre-Funded Warrant (Filed With SEC on August 2, 2022)

Amendment No. 1 to the Asset Acquisition Agreement, dated July 20, 2022, by and among Timber Pharmaceuticals LLC, Patagonia, Jonathan Rome and Zachary Rome (Filed With SEC on July 26, 2022)

Underwriting Agreement, dated November 2, 2021 by and between Timber Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on November 4, 2021)

Form of Warrant (Filed With SEC on November 4, 2021)

Form of Pre-funded Warrant (Filed With SEC on November 4, 2021)

Form of Restricted Stock Award Agreement (Filed With SEC on March 23, 2021)

Form of Restricted Stock Unit Award Agreement (Filed With SEC on March 23, 2021)

Form of Nonqualified Stock Option Grant Agreement (Filed With SEC on March 23, 2021)

Timber Pharmaceuticals, Inc. 2020 Omnibus Equity Incentive Plan (Filed With SEC on March 23, 2021)

Description of Capital Stock (Filed With SEC on March 23, 2021)

Offer Letter, dated January 19, 2021, between the Company and Alan Mendelsohn, M.D (Filed With SEC on January 25, 2021)

Form of Waiver Agreement, dated as of November 19, 2020, by and between Timber Pharmaceuticals, Inc. and the Holders (Filed With SEC on November 20, 2020)

Amended and Restated Registration Rights Agreement, dated July 17, 2020, by and between Timber Pharmaceuticals, Inc. and certain buyers named therein (Filed With SEC on August 18, 2020)

Form of B Warrant (Filed With SEC on June 3, 2020)

Form of A Warrant (Filed With SEC on June 3, 2020)

Offer Letter, dated March 31, 2020, between Joseph Lucchese and Timber Sub (Filed With SEC on May 22, 2020)

Offer Letter, dated March 31, 2020, between Michael Derby and Timber Sub (Filed With SEC on May 22, 2020)

Offer Letter, dated March 31, 2020, between Zachary Rome and Timber Sub (Filed With SEC on May 22, 2020)

Form of Amendment No. 1 to Securities Purchase Agreement, dated April 27, 2020, by and among Timber, BioPharmX and certain investors parties thereto (Filed With SEC on April 27, 2020)

Description of Capital Stock (Filed With SEC on March 23, 2020)

Offer Letter, dated June 20, 2019, between John Koconis and Timber (Filed With SEC on February 20, 2020)

Asset Acquisition Agreement, dated February 28, 2019, by and among Timber, Patagonia, Johnathan Rome and Zachary Rome (Filed With SEC on February 20, 2020)

Asset Acquisition Agreement, dated June 26, 2019, by and among Timber, Patagonia, Jonathan Rome and Zachary Rome (Filed With SEC on February 20, 2020)

Management Services Agreement, dated January 1, 2020, by and between TardiMed and Timber (Filed With SEC on February 20, 2020)

Consulting Services Agreement, dated January 8, 2020, by and between Timber Pharmaceuticals, LLC and AT Consulting LLC (Filed With SEC on February 20, 2020)

Sublease Agreement between BioPharmX, Inc. and Full Cycle Bioplastics Inc., dated February 14, 2020 (Filed With SEC on February 18, 2020)

Form of Exchange Agreement, dated January 28, 2020, between BioPharmX and the Holders (Filed With SEC on January 29, 2020)

Form of Stockholder Support Agreement (Filed With SEC on January 29, 2020)

Note, dated January 28, 2020, made by BioPharmX in favor of Timber (Filed With SEC on January 29, 2020)

Bridge Loan Credit Agreement, dated January 28, 2020, between BioPharmX and Timber (Filed With SEC on January 29, 2020)

Bridge Warrant To Purchase Common Stock, dated January 28, 2020, made by BioPharmX in favor of Timber (Filed With SEC on January 29, 2020)

Agreement and Plan of Merger and Reorganization, dated January 28, 2020, among BioPharmX, Timber and Merger Sub (Filed With SEC on January 29, 2020)

Consulting Agreement between Kin Chan and BioPharmX, Inc., as amended (Filed With SEC on September 9, 2019)

Offer Letter between Steven Bosacki and the Company, effective as of July 16, 2019 (Filed With SEC on July 17, 2019)

Capital on DemandTM Sales Agreement, dated May 16, 2019, by and between BioPharmX Corporation and JonesTrading Institutional Services LLC (Filed With SEC on May 16, 2019)

Placement Agency Agreement (Filed With SEC on March 21, 2019)

Form of Securities Purchase Agreement (Filed With SEC on March 21, 2019)

BioPharmX Corp (51)